https://www.selleckchem.com/products/dt-2216.html
BRCA1/2 screening for all triple-negative breast cancer (TNBC) patients younger than 60years may still be an economic burden in China. Further evidences that include incidence and outcome of BRCA1/2 pathogenic variants (PV) screened based on younger age or family history (FH) are worth discussing for improving the cost-effectiveness of BRCA1/2 testing in Chinese TNBC. We aimed to investigate the prevalence of germline and tumor BRCA1/2 PV based on age screening in Chinese TNBC patients. Paired blood and tumor DNA from 124 unselected Chi
Aimer
Commentaire
Partagez
